A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03693378
• Other study ID #: PanFAM-1
• Status: Completed
• Start date: January 19, 2016
• Est. completion date: November 12, 2021

Study information

• Verified date: August 2020
• Source: Immunovia, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.

Description:

PanFAM-1 is a prospective, multi-center, investigational study, designed to assess the performance of the IMMray™ PanCan-d test in early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk populations. Specifically, the IMMray PanCan-d test uses state of the art machine learning algorithms to condense the multiple fluorescence data points generated by the test to a simple yes/no result. Thus, a highly complex statistical model uses the multi-dimensional nature of the test to generate a score, which is called a decision value. The score is compared to the established cut-off value for the test to inform the operator whether the patient sample is positive or negative for PDAC. This study will validate and evaluate the performance of the IMMray PanCan-d test in comparison to standard of care imaging approaches that are currently used in PDAC disease surveillance. Subjects in this study will be recruited from several European and North American research sites that have a PDAC surveillance program or established protocol for monitoring individuals considered to be at a high-risk for developing pancreatic cancer. Any subject that shows disease progression while on-study will be removed from the study to receive standard of care per institutional guidelines. Overall, this study poses minimal risk to subjects. The PanFAM-1 study is an adaptive study design over two approximately 18 month intervals, which are separated by an interim analysis to evaluate diagnostic accuracy of the IMMray PanCan-d test. This study is an observational period in which blood collections from eligible subjects will be evaluated using the IMMray PanCan-d test. Subjects will undergo scheduled imaging assessment and clinical evaluation consistent with the resarch sites' PDAC surveillance program. Subject data derived from the IMMray PanCan-d test during this portion of the study will be delayed from time of initial blood collection until the samples are analyzed. The analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging assessments performed as part of standard of care PDAC surveillance. The study will only proceed to the interventional period if the interim analysis indicates that the diagnostic accuracy of the IMMray PanCan-d test is capable of detecting PDAC in high-risk subjects with the same or better ability as standard of care imaging. If at any time imaging assessments are considered positive for clinical disease then, regardless of IMMray PanCan-d test results, subjects will be managed according to institutional guidelines. All scheduled blood collections for purposes of this study will be halted and subjects will be removed from the study upon confirmation of PDAC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1349
• Est. completion date: November 12, 2021
• Est. primary completion date: November 12, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Ability to understand and the willingness to sign a written informed consent document

2. Individuals with the following family phenotype and age:

1. Two or more relatives with pancreatic adenocarcinomas (PDAC) on the same side of the family, where two PDAC-affected individuals are first degree related (FDR) + at least one PDAC-affected individual is a FDR of the Participant (=50 years old OR 10 years before onset in family)

2. Two affected FDR with PDAC (=50 years old OR 10 years before onset of an FDR)

3. Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic + one FDR or secondary degree related (SDR) with PDAC (=50 years old OR 10 years before onset of an FDR and SDR)

4. Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A (=50 years old)

5. Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (=35 years old)

6. Lynch syndrome (HNPCC) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (=50 years old OR 10 years before onset of an FDR or SDR)

7. Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis (=40 years old)

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Adenocarcinoma
• Dysplastic Nevus Syndrome
• Familial Pancreatic Cancer
• FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
• Melanoma
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Locations

Country	Name	City	State
Canada	The Research Institute of the McGill University Health Centre	Montréal
Spain	University Hospital Ramon y Cajal	Madrid
Spain	University Hospital Santiago De Compostela	Santiago De Compostela
Sweden	Sahlgrenska University Hospital	Gothenburg
Sweden	Linköping University Hospital	Linköping
Sweden	Karolinska University Hospital	Stockholm
Sweden	Umeå University Hospital	Umeå
United Kingdom	University Collage London Hospital	London
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Chicago Medical Center	Chicago	Illinois
United States	The Ohio State University	Columbus	Ohio
United States	Yale University	New Haven	Connecticut
United States	Columbia University	New York	New York
United States	Mount Sinai Hospital	New York	New York
United States	New York University Hospital	New York	New York
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Oregon Health & Science University	Portland	Oregon
United States	University of Utah	Salt Lake City	Utah
United States	Stanford Gastroenterology and Hepatology	Stanford	California
United States	University of Massachusetts	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Immunovia, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Spain,  Sweden,  United Kingdom, 

References & Publications (1)

Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol. 2018 Oct 1;36(28):2887-2894. doi: 10.1200/JCO.2017.77.6658. Epub 2018 Aug 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Validation of IMMray™ PanCan-d test	Demonstrate that the IMMray PanCan-d test is equal or better than the reference standard imaging procedures for early detection of PDAC in asymptomatic high risk individuals	Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first
Secondary	Evaluation of the IMMray™ PanCan-d test performance	Point Estimates and 95% confidence intervals	Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first